Second-Line Bosutinib Is Effective and Feasible in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) - an Analysis of a Subcohort of the Bodo Trial (CML-VII-study of the German CML Study Group)

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Blood

Topics

Medicine

Cancer Oncology

Immunology

Internal Medicine

Hematology

Show all topics

DOI

10.1182/blood-2024-208687